Want to see HYFT full AI Analyst Report?
HYFT Stock Chart & Stats
$1.42
$0.18(15.25%)
At close: 4:00 PM EDT
$1.42
$0.18(15.25%)
Day’s Range― - ―
52-Week Range$0.99 - $2.99
Previous CloseN/A
Volume983.42K
Average Volume (3M)301.42K
Market Cap
$60.77M
Enterprise Value$57.43M
Total Cash (Recent Filing)$7.63M
Total Debt (Recent Filing)$3.49M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Dec 10, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding47,111,668
10 Day Avg. Volume486,788
30 Day Avg. Volume301,424
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)6.39
Price to Sales (P/S)4.89
P/FCF Ratio-5.92
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit5.84
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$4.33Price Target Upside205.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$18.46M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthFive consecutive quarters of year-over-year growth indicate sustained commercial traction rather than a single-period increase. If maintained, expanding revenue can improve operating leverage, support broader customer adoption, and help MindWalk fund platform development while moving toward breakeven.
Pharmaceutical Customer BaseDeep relationships with leading pharmaceutical companies and a track record spanning clinical-stage molecules provide commercial credibility in a regulated market. This customer access can support recurring platform adoption, validation of MindWalk’s technology, and durable expansion across drug-development programs.
Platform Partnership ModelShifting toward platform partnerships may broaden MindWalk’s economic participation beyond discrete project fees through milestones, royalties, and asset-linked value. A successful model could deepen customer relationships, increase revenue durability, and make the company’s technology more embedded in discovery workflows.
Bears Say
Persistent Losses And Cash BurnLarge recurring operating and free-cash-flow outflows show that MindWalk is not yet funding operations internally. Continued burn can consume liquidity, increase reliance on external financing, and limit investment flexibility unless revenue growth and cost discipline improve materially.
Severe Equity ErosionThe substantial decline in shareholders’ equity reflects the cumulative effect of sustained losses and leaves a much smaller capital buffer against future setbacks. If losses continue, balance-sheet resilience and financing flexibility may weaken even though current debt leverage appears manageable.
Uncertain ReefIQ CommercializationReefIQ’s long-term revenue opportunity remains unproven while enterprise deployments are still under negotiation. Delays in security, legal, procurement, or data-governance approvals could defer recurring revenue, prolong cash burn, and make near-term growth difficult to forecast.
MindWalk Holdings News
HYFT FAQ
What was MindWalk Holdings’s price range in the past 12 months?
MindWalk Holdings lowest stock price was $0.99 and its highest was $2.99 in the past 12 months.
What is MindWalk Holdings’s market cap?
MindWalk Holdings’s market cap is $60.77M.
When is MindWalk Holdings’s upcoming earnings report date?
MindWalk Holdings’s upcoming earnings report date is Dec 10, 2026 which is in 50 days.
How were MindWalk Holdings’s earnings last quarter?
MindWalk Holdings released its earnings results on Sep 14, 2026. The company reported -$0.091 earnings per share for the quarter, missing the consensus estimate of -$0.054 by -$0.037.
Is MindWalk Holdings overvalued?
According to Wall Street analysts MindWalk Holdings’s price is currently Undervalued.
Does MindWalk Holdings pay dividends?
MindWalk Holdings does not currently pay dividends.
What is MindWalk Holdings’s EPS estimate?
MindWalk Holdings’s EPS estimate is -0.06.
How many shares outstanding does MindWalk Holdings have?
MindWalk Holdings has 47,111,668 shares outstanding.
What happened to MindWalk Holdings’s price movement after its last earnings report?
MindWalk Holdings reported an EPS of -$0.091 in its last earnings report, missing expectations of -$0.054. Following the earnings report the stock price went down -13.158%.
Which hedge fund is a major shareholder of MindWalk Holdings?
Currently, no hedge funds are holding shares in HYFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (205.16% Upside)
$4.33 (205.16% Upside)
Blogger Sentiment
Neutral
HYFT Sentiment 67%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.34%
12-Months-Change
Fundamentals
Return on Equity
-144.31%
Trailing 12-Months
Asset Growth
-58.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MindWalk Holdings
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
HYFT Company Deck
HYFT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive, supported by 21% year-over-year revenue growth, five consecutive quarters of year-over-year growth, gross margin expansion to 59%, progress launching ReefIQ, a strong pharmaceutical customer base, clinical validation, platform partnership traction, and a USD 30 million non-dilutive financing commitment. The main negative factors were the increased $6.1 million loss, higher operating expenses, a lower cash balance, uncertain and potentially lumpy timing for ReefIQ revenue, and the absence of announced enterprise contracts or specific closing timelines.View all HYFT earnings summariesHYFT Stock 12 Month Forecast
Average Price Target
$4.33
▲(205.16% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
9.64% Insiders
0.14% Mutual Funds
<0.01% Other Institutional Investors
89.93% Public Companies and
Individual Investors